There are significant Ca 2ϩ -independent increases in extracellular glutamate and aspartate during various CNS insults such as ischemia and anoxia. However, the cellular sources of such presumed nonvesicular excitatory amino acid (EAA) release have not been established. To further explore potential mechanisms and sites for EAA release, we studied the release of preloaded [
Glutamate and aspartate are the major excitatory neurotransmitters in the mammalian CNS (Fonnum, 1984; Erecinska and Silver, 1990) . There is tight regulation of extracellular glutamate levels, which are normally measured to be ϳ1-2 M (Erecinska and Silver, 1990) . High-affinity Na ϩ -dependent glutamate transporters are thought to be primarily responsible for maintaining this low extracellular glutamate concentration and are present on both neurons and astrocytes. There are now known to be at least three different subtypes of glutamate transporters (GLAST-1, GLT-1 and EAAC1) in the rat, as well as an EAAT4 isoform in human cerebellum (Pines et al., 1992; Kanai and Hediger, 1992; Storck et al., 1992; Wadiche et al., 1995) . Recent work has suggested that GLAST-1 and GLT-1 are primarily responsible for maintaining low [glu Ϫ ] o (Nicholls and Attwell, 1990; Rothstein et al., 1994) . Glutamate levels have been shown to increase during ischemia and other CNS insults (Benveniste et al., 1984; Wahl et al., 1994) , and if in vitro extracellular glutamate levels increase Ն100 M for longer than 5 min, neuronal death can occur (Choi et al., 1987) .
It has been considered that there are at least three glutamate pools that can contribute to glutamate release during CNS insults. One is Ca 2ϩ -dependent vesicular release from nerve terminals (Benveniste et al., 1984) . The other two are cytosolic and can be released by Ca 2ϩ -independent reversal of the glutamate transporter (Nicholls and Attwell, 1990; Szatkowski et al., 1990; Attwell et al., 1993) . Another mechanism seen in primary astrocyte cultures is a swelling-induced, Ca 2ϩ -independent release (Kimelberg et al., 1990) . It has been proposed that inhibition of uptake and/or reversal of the glutamate transporter can occur when the electrochemical gradients for Na ϩ and K ϩ are disrupted during CNS insults; these effects can contribute significantly to the increased [glu] o seen during pathological states (Hansen, 1985; Ikeda et al., 1989; Attwell et al., 1993; Wahl et al., 1994) .
This study focuses on showing how astrocytes might contribute to glutamate release during ischemia by measuring the efflux of preloaded [
3 H]-D-aspartate under varying extracellular [K ϩ ] and extracellular and intracellular [Na ϩ ], using primary astrocyte cultures. A previous study from this laboratory has shown that when astrocytes were exposed to 100 mM KCl HEPES buffer not only was uptake inhibited, but [
3 H]-D-aspartate was released in a biphasic manner (Kimelberg et al., 1995) . We proposed then that the initial transient phase of [ 3 H]-D-aspartate release could be a result of reversal of the glutamate transporter, and the second phase was a KCl swelling-induced release process. In the present study, we used manipulations of the ion gradients and pharmacological treatments to further support this hypothesis. In addition, when we added ouabain to increase [Na ϩ ] i , we found that reversal of the glutamate transporter was the prominent form of glutamate release and that its sensitivity to varying [KCl] o was markedly increased.
MATERIALS AND METHODS
[ 3 H]-D-aspartate was obtained from Amersham (Arlington Heights, IL). All other chemicals were obtained from Sigma (St. Louis, MO). Culture media and materials were from Gibco.
Cell culture. Primary astrocyte cultures were prepared from the cerebral cortex as described by Frangakis and Kimelberg (1984) . In brief, the cerebral hemispheres of newborn rats (Sprague Dawley) were removed and the meninges carefully dissected away. The cortices were turned over from front to back exposing the hippocampus, which is removed along with the meninges from the underside of the hemispheres. The tissue was extracted with three to five 10-min dissociations with Dispase II in Joklik S-MEM (Boehringer Mannheim Biochemicals, neutral protease, Dispase Grade II). The first extraction was discarded, and DNase (3 drops of 4 mg/ml for 10 ml of S-MEM) was added for the second extraction. The dissociated cells were seeded and grown on poly D-lysine-coated 18 ϫ 18 mm coverslips (Bellco Biotechnology, Vineland, NJ). Cultures were used after approximately 3-4 weeks when the cells reached a confluent monolayer. Immunocytochemistry showed Ͼ95% of the cells stained positively for the astrocytic marker glial fibrillary acidic protein.
Efflux measurements. Astrocytes grown on coverslips were incubated overnight in 2.5 ml of MEM containing 10% horse serum, together with 4 Ci/ml of [ 3 H]-D-aspartate (1 mCi/ml; specific activity, 86.4 mCi/mg aspartate). In some experiments, 8 Ci/ml Na 2 51 CrO 4 was also added to the incubation medium (1 Ci/ml; specific activity, 50 mCi/mg Cr). The appearance of 51 Cr in the perfusate during release experiments can be used to determine whether an increase in [
3 H]-D-aspartate release is a result of cell detachment or lysis (Kimelberg et al., 1993) . Radiolabeled D-aspartate is used as a nonmetabolizable marker for the intracellular glutamate and aspartate pools. Both of these amino acids are transported on the same carrier protein and label the nonvesicular pool of EAAs (Erecinska and Silver, 1990; Barbour et al., 1993) . D-glutamate is not taken up by the transporter. The loaded coverslips were inserted into a Lucite perfusion chamber with a cut out depression in the bottom for the 18 ϫ 18 mm glass coverslips. The chamber has a screw top and when screwed down leaves a space above the cells of around 100 m. This perfusion chamber is well suited for measuring the release of [
3 H]-Daspartate from astrocytes in response to various KCl buffers because the volume in the chamber is relatively small (18 ϫ 18 ϫ 0.1 mm ϭ 32.4 l). This chamber allows a complete change of the perfusing buffer within 2 min, as determined by removal of a trypan blue solution.
The cells were perfused with HEPES-buffered solution consisting of 140 mM NaCl, 3.3 mM KCl, 0.4 mM MgSO 4 , 1.3 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 10 mM (ϩ)D-glucose, 25 mM HEPES. NaOH (10 N) was used to pH the buffers to 7.4. Increased KCl buffers were made by replacing NaCl with KCl. The osmolarity of all buffers were measured by a freezing point osmometer (Advanced Instruments, Needham Heights, MA); the osmolarities were 285-290 mOsm. Sucrose was added to make any adjustments in osmolarity to exactly 290.
The lucite chamber and a fraction collector were placed in an incubator set at 37ЊC, and the perfusate was collected in 1 min intervals. At the end of the experiment, the cells were digested off the coverslip with 1 N NaOH. The radioactivity was counted using a Packard Beckman LS 3801 Liquid Scintillation Analyzer (Beckman Instruments, Irvine, CA). Percent fractional release for each time point was calculated by summing the radioactive counts from the end time point to the beginning of each minute plus the radioactivity left in the cell digest and dividing the dpms released in each minute by these summed dpms. The number of release experiments for each condition ranged from two to four as indicated in each figure legend.
For Figure 1 B, a paired t test was used to compare corresponding times for the different conditions, and all error bars are SEM. Two separate components of release were seen, and the initial eight points encompassing the first peak and the last eight points representing the second peak were used in analysis of the effects of varying [KCl] . The middle four points were not considered because of uncertainty of contribution of either component to this [
3 H]-D-aspartate release. Basal release, which was the constant release rate before increasing KCl, was then subtracted from all values.
Intracellular Ca 2ϩ measurements. Intracellular [Ca 2ϩ ] i was measured using a monochromator-based spectrophotofluorimetric system (Model RF D-4010 Deltascan, PTI, South Brunswick, NJ), with cells loaded with fura-2. The excitation wavelengths were set at 340 and 380 nm with a 2 nm bandwidth. The emission was measured at 505 nm. A 1 mM stock of fura-2 was made by dissolving the powder in a DMSO stock solution, which was then divided into 20 l aliquots in Eppendorf tubes. The vials were kept frozen at Ϫ20ЊC until use. Three-to 4-week-old primary astrocyte cultures grown on 25 mm glass coverslips were incubated with 10 M fura-2 for 30 min in normal HEPES buffer, after which the cells were washed to remove unloaded fura-2.
The coverslips were placed in a PDMI-2 open perfusion chamber (Medical Systems, Greenville, NY). Temperature was maintained at 36.5ЊC Ϯ 0.5ЊC by a TC-202 bipolar temperature controller (Medical Systems, Greenville, NY). Buffers were changed by adding 1 ml of prewarmed buffers (approximately 36ЊC) by a pipette to 0.5 ml bath solution in the coverslip dish. The 0.5 ml volume was maintained by aspiration (LU-ASP, Medical Systems, Greenville, NY). The field being measured was a portion of a single cell that excluded the nucleus and any bright dots of fluorescence that might be a result of dye sequestration.
RESULTS

Enhancement of the initial phase of release with ouabain
Understanding the effects of the varying K ϩ and Na ϩ gradients on the glutamate transporter has been facilitated by recent understanding that both of these ions contribute to the activity of the transporter, as shown in the model in Figure 9 . For each glutamate transported inward there is cotransport of one positive charge, which also makes the transporter dependent on membrane potential (Nicholls and Attwell, 1990 ; Szatkowski et al., 1990; Attwell et al., 1993; Wadiche et al., 1995) . For reversal, the gradients are simply switched. Figure 1 A shows the release pattern of [ 3 H]-D-aspartate from astrocyte cultures when exposed to 100 mM KCl buffer. The initial release component (first peak or shoulder) is small and transient, followed by a slower but progressively increasing phase of release. When the cells were exposed to 100 mM K ϩ but with reduced Cl Ϫ to keep the K ϩ ϫ Cl Ϫ product constant, different release characteristics were observed with only the initial component being barely detectable (Fig. 1 A, middle exposure) . In the product constant buffer Cl Ϫ was replaced with the impermeant anion gluconate, which cannot enter the cell with K ϩ to cause swelling (Boyle and Conway, 1941; Hodgkin and Horowicz, 1959) .
If the initial peak of release is reversal of the glutamate transporter, then increasing intracellular Na ϩ concentration in conjunction with exposure to high extracellular K ϩ should increase the initial phase of release. Therefore, we used ouabain, which has been shown to increase [Na ϩ ] i in primary astrocyte cultures (Kimelberg et al., 1979; Rose and Ransom, 1996) . This increase was also verified in experiments using the Na ϩ -sensitive dye SBFI-AM (data not shown), as reported by others (Rose and Ransom, 1996) . Ouabain was used at concentrations of 1 to 1.5 mM, because rat astrocyte cells need ϳ1 mM ouabain for complete inhibition of the pump (Kimelberg et al., 1979) . In rat hippocampal astrocyte cultures, [Na ϩ ] i was 42 mM after 10 min of ouabain exposure (Rose and Ransom, 1996) . In Figure 1 B, it can be seen that the initial phase of release is significantly increased with a 10 min, 1 mM ouabain pretreatment, and then exposure to 100 mM KCl ϩ 1 mM ouabain, as compared to 100 mM KCl without ouabain (second exposure). These data are the mean Ϯ SEM of four separate experiments.
Because ouabain increased the first peak of release, it enabled us to more clearly examine the effect of different experimental manipulations on the first component of release. If the size of the first component depends on [Na ϩ ] i , then increasing ouabain pretreatment time from 10 to 40 min should cause an increase in the initial release component as intracellular Na ϩ progressively increases (Kimelberg et al., 1979; Rose and Ransom, 1996) . This occurred as shown in Figure 2 .
We also reexamined the effect of constant K ϩ ϫ Cl Ϫ product exposure in the presence of 1.5 mM ouabain. In Figure 3A (middle exposure), there is a sharp increase in release, followed by a rapid return to baseline while still in 100 mM K ϩ ϫ Cl Ϫ buffer. This shows that keeping the K ϩ ϫ Cl Ϫ product constant prevents the second K ϩ -induced swelling release. The initial component is thought to be influenced by [K ϩ ] o , [Na ϩ ] i , and the membrane potential, but not by swelling (Nicholls and Attwell, 1990 ). In our previous study (Kimelberg et al., 1995) , we found also that L-644,711 inhibited the second component of K ϩ -induced release while leaving the initial component unaffected in the absence of ouabain. In Figure 3B , we show this more clearly because the augmented first component in the presence of ouabain was unaffected by exposure to L-644,711, whereas the second component was completely inhibited.
Inhibition of initial phase of [ 3 H]-D-aspartate release by an amino acid transport inhibitor
In Figure 4 , we show an example of experiments designed to determine whether the glutamate/aspartate transport inhibitor THBA (DL-threo-␤-hydroxyaspartate) could inhibit the initial phase of [
3 H]-D-aspartate release without affecting the second component. A 40 min preincubation period was used to load THBA into astrocytes (Fig. 4 B) . Because THBA is a competitive inhibitor, it needs to act from the same side as the intracellularly Figure 4 A indicate the presence of the initial phase of release caused by 100 mM KCl ϩ ouabain before, and its expected position after, exposure for 40 min to 1 mM THBA. The small peak seen when THBA is first added (dashed arrow) and the subsequent elevated [
3 H]-D-aspartate release is likely a result of heteroexchange on the EAA transporter (McMahon et al., 1989) . The second phase of [
3 H]-D-aspartate release was unaffected by the presence of THBA. The augmentation of this peak upon a second exposure to 100 mM KCl was seen both with and without THBA (see Discussion).
Sensitivity of [ 3 H]-D-aspartate release to increasing [KCl]
To assess the potential relevance of high K ϩ induced release, it is important to determine its sensitivity to varying [KCl] . Figure 5 , A and B, shows the dependency of release on KCl concentration in the absence of ouabain. Figure 6 A-E shows the results with a 10 min, 1.5 mM ouabain pretreatment, followed by various KCl concentrations in the continued presence of ouabain (middle or initial exposures as indicated), compared to release without ouabain pretreatment in the same experiment. Each panel shows two individual experiments for the KCl concentrations indicated. In Figure 6 F, we have plotted the data from Figures 5 and 6 A-E. The initial eight time points of release were plotted as the first component in the presence of ouabain (solid circles). The maximum release occurred at ϳ50 mM KCl and the half-maximal release at ϳ25 mM K ϩ . The second release component was tested at 100 mM KCl and was not significantly affected by ouabain (large black square). Clearly, there was an increased sensitivity to [K ϩ ] o , as well as an increase in magnitude of the initial response, so that the sensitivity to K ϩ is now greater than in the absence of ouabain. We attribute this to increased [Na ϩ ] i . Release not a result of low extracellular Na ؉ As a control it is important to determine that the reduction in extracellular [Na ϩ ] when replaced with K ϩ does not by itself cause [
3 H]-D-aspartate release. Figure 7A shows that when 100 mM Na ϩ was replaced by NMDG.Cl the [ 3 H]-D-aspartate release from the first component was less than when Na ϩ in the media was replaced by 100 mM KCl. This experiment was in the absence of ouabain. In Figure 7B , the lack of any stimulation of the first component with a reduction in [Na ϩ ] o is shown more clearly when ouabain was present. It can also be seen that the second phase of [
3 H]-D-aspartate release (swelling-induced release) was also not seen during exposure to low Na ϩ -containing The data points were calculated by summing the first and last eight release data points of a KCl exposure, and the basal release was then subtracted as described in Materials and Methods. The numbers in parentheses represent the number of experiments performed for those data points shown Ϯ SEM. The rest of the data points represent means of two experiments.
buffers. This is to be expected because no Donnan swelling should occur when K ϩ is not increased (Hodgkin and Horowicz, 1959) .
Ca
2؉ dependency
In terms of the potential relevance of these processes to Ca 2ϩ -independent release of amino acids in ischemia and other pathological states, it is important to determine whether any of these release mechanisms are sensitive to the omission of extracellular Ca 2ϩ . Figure 8 A shows the results of four efflux experiments, where exposures to increased K ϩ was done in the presence and absence of Ca 2ϩ , respectively. It can be seen that there was increased [
3 H]-D-aspartate release during the first phase of high K ϩ exposure when the cells were exposed to a nominally Ca 2ϩ -free solution plus 0.1 mM EGTA ϩ 1 M thapsigargin. Thapsigargin was present to eliminate any contribution from Ca 2ϩ released from intracellular stores; this was verified by fura-2 experiments to measure changes in [Ca 2ϩ ] i as shown in Figure 8 B. The cells were first equilibrated for 30 min, and fresh buffer added at t ϭ 30 min. The increasing baseline after 30 min was a result of a temperature difference between the Iso HEPES buffer added and the bath buffer. As can be seen, there was no Ca 2ϩ response to 100 mM KCl in Ca 2ϩ -free media also containing EGTA, ouabain, and thapsigargin. Reexposure to Ca 2ϩ -containing medium caused a sharp transient increase. When the cells were then exposed to Ca 2ϩ -containing media and then to ouabain, followed by 100 mM KCl ϩ ouabain, an initial sharp Ca 2ϩ transient with subsequent oscillations was seen. This behavior was representative of three experiments.
DISCUSSION
Release of EAAs from glial cells
In ischemia and hypoxia, extracellular [K ϩ ] has been shown to increase to 80 mM or higher, and extracellular [Na ϩ ] decreases concomitant with an increased [Na ϩ ] i (Somjen, 1979; Hansen, 1985) . This is presumed to be mainly a result of the inactivation of the Na ϩ /K ϩ ATPase pump caused by the depletion of ATP (Shimizu et al., 1993) . Thus, the manipulation of ion gradients in our experiments model the ionic changes that occur during these CNS pathologies. Szatkowski et al. (1990) (Fig. 9) . In support of this model, when the cells were pretreated with ouabain to raise [Na ϩ ] i , there was a marked increase in the first without any effect on the second component. Ouabain pretreatment also increased the sensitivity of release of the first component to extracellular [K ϩ ] exposure compared to without ouabain pretreatment. A rise to 6.0 -10 mM KCl, which is in the range of [K ϩ ] o surrounding epileptic neurons (Somjen, 1979) , caused an increase in basal [
3 H]-D-aspartate release when cells were pretreated for 10 min with 1 mM ouabain.
Identification of the first peak as reversal of the EAA transporter was supported by the use of a potent competitive blocker of glutamate uptake, THBA. THBA was first loaded inside the cell utilizing the EAA transporter operating in its heteroexchange mode (McMahon et al., 1989) . Once inside the cell, THBA competes with and reduces the initial phase of [ 3 H]-D-aspartate release (Fig. 4) . (Walz, 1987; Sontheimer, 1995) . However, a recent study by Rose and Ransom (1996) using cultured hippocampal astrocytes has shown that TTX had only a small effect on [Na ϩ ] i , and in only 15% of the cells studied.
Critical role of [Na
It will be important to determine which of the two currently known astrocytic glutamate transporter subtypes, GLAST-1 or GLT-1, is expressed in primary cultures. Kondo et al. (1995) have recently shown that primary astrocyte cultures prepared from the cerebral cortices of rat pups express GLAST-1 and not GLT-1, which is the primary transporter expressed in astrocytes of the adult rat cortex (Rothstein et al., 1994) . However, there is no evidence thus far to suggest that there would be any difference in reversal characteristics between the different isoforms. This would imply that neurons can also release EAAs by reversal of the EAAC1 transporter. However, there is no direct evidence for this as yet, and also no evidence that neurons can release EAAs by a swelling mechanism.
Swelling-induced release
The second phase of release seems to be independent of the first. It is likely to be a result of cell swelling because high KCl causes swelling of astrocytes (Walz, 1987) , as it does in other cells (Hodgkin and Horowicz, 1959) . L-644,711, an anion channel blocker that inhibits hypotonic media-induced swelling release of EAAs (Kimelberg et al., 1990) H]-D-aspartate release. Also, in complete contrast to the first component, the magnitude of the second component is not affected by ouabain. The second phase of release may be important because astrocytic swelling is prominent and occurs rapidly after the induction of anoxia, ischemia, hypoglycemia, and head trauma (Kimelberg, 1992) and seems detrimental to survival because when swelling was inhibited with L-644,711, an anion channel inhibitor (Barron et al., 1988) , there was decreased mortality in an animal head injury model (Kimelberg et al., 1989) . There are at least two mechanisms of action that might explain the effect of L-644,711 on the second release component. One is that being a Cl Ϫ channel blocker that inhibits Cl Ϫ influx, swelling because of Donnan forces is prevented. The second mechanism would be that L-644,711 blocks the release of [
3 H]-D-aspartate via a proposed swellingactivated anion channel that allows passage of amino acids (Jalonen, 1993 Ca 2ϩ -free media with and without thapsigargin (see Fig. 8 A, data not shown for latter condition) showed no inhibition of either the first or second release component. Indeed, the initial phase of release seems to be potentiated compared to Ca 2ϩ containing 100 mM KCl. It supports the view that Ca 2ϩ -independent release mechanisms can increase glutamate levels by both reversal of the EAA transporter and swelling-induced release in pathological states. In most experiments, potentiation of both components occurred during identical second or third KCl exposures. The mechanisms of these are unknown, although the enhanced initial phase of release could be caused by phosphorylation of the EAA transporter, which increases the V max in glial cells (Casado et al., 1991) .
Conclusions
Since the initial studies of Drejer et al. (1985) , it has been assumed that the increased [EAA] o seen in ischemia and other pathological studies is mainly a result of release from nerve terminals. There are two glutamate pools found in neurons. One is vesicular, located in the nerve terminals and is dependent on Ca 2ϩ and ATP for release (Nicholls and Attwell, 1990 ). The second is free glutamate in the cytosol, and this can be released by reversal of the glutamate transporter. Recent studies have shown that with ischemia Ͼ20 min duration EAA release is independent of Ca 2ϩ and even within the first 10 min about half of the release is independent of Ca 2ϩ (Wahl et al., 1994) . Using immunocytochemistry, Aas et al. (1995) and Torp et al. (1991) have shown that the neuronal cytosolic glutamate pool, but not the vesicular glutamate pool, decreases in neurons in ischemia supporting the hypothesis that vesicular release is inhibited because of the lack of ATP. There was a concomitant increase in glutamate labeling in astrocytes and, therefore, astrocytes could be acting as a sink for the increased extracellular glutamate. This increase could be a result of the fact that glutamine synthetase, which normally breaks down glutamate to glutamine, is inhibited by the reduction in ATP. However, these histological studies do not address the question of flux. If the increased glutamate levels in astrocytes is available for release, then astrocytes could play a significant role in increasing [glu Ϫ ] o by either of the two mechanisms described in this paper. In addition, our method of measuring preloaded [ 3 H]-D-aspartate release does not enable a quantitative measurement of EAA release. This is important in terms of functional significance and can best be addressed by studying actual glutamate release in vivo. In vivo microdialysis studies using manipulations to alter the relative amounts of terminal versus astrocytic release and pharmacological manipulations to identify the different mechanisms should help resolve these important issues.
